IMA Group Continues National Growth with Acquisition of Amici Clinical Research

Newest acquisition adds two clinical trial sites to IMA’s clinical research network

TARRYTOWN, N.Y.--(BUSINESS WIRE)--The IMA Group (IMA) announced today the acquisition of Amici Clinical Research, a clinical trials company with two New Jersey sites in Raritan and Hoboken. Expanding IMA’s metro New York presence, Amici brings therapeutic expertise in fatty liver, cardiovascular, pulmonary, and neurologic diseases to IMA Clinical Research. The company also has extensive experience conducting endocrinology, dermatology, and vaccine studies, among the fastest-growing categories of clinical research today.

The acquisition of Amici expands IMA’s footprint in the Northeast and enhances its breadth of therapeutic coverage. It also adds to IMA’s growing clinical research network and more than 100 brick-and-mortar medical offices. The acquisition moves IMA a step closer to realizing its vision to reach people everywhere, as it partners with its sponsors on site-based, hybrid, and decentralized clinical trials.

Amici was founded in 2015 and is led by David Rodin, CEO, Robert Falcone, M.D., Chief Medical Officer, and Anthony Frisoli, M.D., Chief Business Development Officer. Rodin and Falcone will join the executive team of IMA Clinical Research, bringing over 55 years of combined experience in clinical care, research and drug development. Both previously held executive positions at Merck and Pfizer.

“We are very pleased to have David and Rob and the highly qualified team of Amici join our Clinical Research Division. Their extensive experience in clinical research and drug development, coupled with their deep industry knowledge, makes them a perfect fit for our executive team and staff as we accelerate the growth of our Clinical Research Division,” said Mark Weinberger, Ph.D., MPH, President and CEO of The IMA Group.

“This acquisition will enable Amici Clinical Research to provide an even higher level of service to a greater number of customers,” said Rodin. Falcone further commented that “IMA’s client-centric culture and vision, along with its complementary clinical strengths and impressive infrastructure, convinced David and me this was a perfect fit for our company and people.”

Financial terms for the two privately held companies were not disclosed. Amici Clinical Research will continue to operate under its current name. In addition to Rodin and Falcone, key leadership, investigators and staff will remain in place. Additional information regarding the capabilities of Amici Clinical Research can be found at www.amicicr.com.

About IMA Clinical Research:

IMA Clinical Research, a division of The IMA Group, is a physician-founded network of integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. With more than 100 sites in the IMA Clinical Trial Network, IMA Clinical Research has extensive capabilities to conduct site-based, hybrid and fully decentralized clinical trials that support the development of safe and effective new treatments. The Clinical Research Division offers access to new advances in pharmacology and biotechnology for research subjects, as well as a robust database of interested clinical trial participants for pharmaceutical and device sponsors. For more information, visit www.imaresearch.com or www.theIMAgroup.com.

Brenna Harrington
Scott Public Relations
706-217-7809